Web Results

www.renalandurologynews.com/.../enzalutamide-increases-overall-survival-in-nmcrpc

The time to subsequent antineoplastic therapy, time to cytotoxic chemotherapy, and chemotherapy-free survival were longer in the enzalutamide group than in the placebo group.

www.cancerabcs.org/advanced-prostate-cancer-blog

Prostate Cancer, PSA Doubling Time Shorter prostate-specific antigen doubling time was significantly associated with shorter metastasis-free survival and overall survival. The development of metastasis was associated with a 3-fold higher risk of death.

www.sciencedirect.com/science/article/pii/S030228382030628X

The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 yr and overall survival (OS) data were immature.

academic.oup.com/annonc/article/18/11/1828/216173

Abstract. Background: We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival in hormone-refractory prostate cancer (HRPC) patients. Patients and methods: Data from 250 consecutive metastatic HRPC patients treated with chemotherapy between February 2000 and November 2006 were retrospectively analysed.

www.renalandurologynews.com/home/news/urology/prostate-cancer/proximal-psa...

PSA Doubling Time Predicts Metastasis, Mortality Risks in CRPC PSA in Midlife Can Predict Later Risk of Prostate Cancer Mets The median metastasis-free survival (MFS) times differed significantly ...

www.hopkinsmedicine.org/.../what-should-i-do-if-my-psa-returns-after-surgery

What the Numbers Mean. If you have a Gleason score of 5-7 Your PSA increased more than two years after surgery AND your PSA doubling time was greater than 10 months: Your chance of NOT developing metastasis (shown in bone positive scan) in:. Three years: 95 percent; Five years: 86 percent; Seven years: 82 percent; OR your PSA doubling time was less than 10 months: Your chance of NOT developing ...

urology.jhu.edu/newsletter/prostate_cancer829.php

If a man's PSA doubled in less than three months, his risk of dying from prostate cancer was much higher than that of a man whose PSA doubling time was more than a year. The same holds true for the time from surgery to the return of PSA: If PSA appeared on a blood test within three years after surgery, that man is at higher risk than is a man ...

jamanetwork.com/journals/jama/fullarticle/198392

An estimated 65% of these men will develop bone metastases within 10 years in the absence of salvage therapy. 2 A rapid PSA doubling time (PSADT), high-grade disease, and a short disease-free interval after radical prostatectomy are prognostic factors associated with the development of metastases in untreated patients with an increasing PSA ...

www.hopkinsmedicine.org/brady-urology-institute/specialties/conditions-and...

If your PSA doubled in less than three months, your risk of dying from prostate cancer is much higher than that of a patient whose PSA doubling time was more than a year. If your PSA appeared on a blood test within three years after surgery, you are at a higher risk than a patient whose PSA returns within five years.

www.cancer.org/cancer/prostate-cancer/treating/psa-levels-after-treatment

Some evidence shows that faster-rising PSA levels may be a sign of cancer. Men who have a PSA level that doubles within a 3-month period tend to have a worse prognosis (outlook) compared to men whose PSA level does not double. This is also known as PSA doubling time. After radiation therapy